A novel program to design siRNAs simultaneously effective to highly variable virus genomes
- PMID: 19422797
- DOI: 10.1016/j.bbrc.2009.04.143
A novel program to design siRNAs simultaneously effective to highly variable virus genomes
Abstract
A major concern of antiviral therapy using small interfering RNAs (siRNAs) targeting RNA viral genome is high sequence diversity and mutation rate due to genetic instability. To overcome this problem, it is indispensable to design siRNAs targeting highly conserved regions. We thus designed CAPSID (Convenient Application Program for siRNA Design), a novel bioinformatics program to identify siRNAs targeting highly conserved regions within RNA viral genomes. From a set of input RNAs of diverse sequences, CAPSID rapidly searches conserved patterns and suggests highly potent siRNA candidates in a hierarchical manner. To validate the usefulness of this novel program, we investigated the antiviral potency of universal siRNA for various Human enterovirus B (HEB) serotypes. Assessment of antiviral efficacy using Hela cells, clearly demonstrates that HEB-specific siRNAs exhibit protective effects against all HEBs examined. These findings strongly indicate that CAPSID can be applied to select universal antiviral siRNAs against highly divergent viral genomes.
Similar articles
-
An antiviral small-interfering RNA simultaneously effective against the most prevalent enteroviruses causing acute hemorrhagic conjunctivitis.Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):58-63. doi: 10.1167/iovs.09-5051. Invest Ophthalmol Vis Sci. 2011. PMID: 20739472
-
Optimal design and validation of antiviral siRNA for targeting hepatitis B virus.Acta Pharmacol Sin. 2008 Dec;29(12):1522-8. doi: 10.1111/j.1745-7254.2008.00891.x. Acta Pharmacol Sin. 2008. PMID: 19026173
-
siVirus: web-based antiviral siRNA design software for highly divergent viral sequences.Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W448-50. doi: 10.1093/nar/gkl214. Nucleic Acids Res. 2006. PMID: 16845046 Free PMC article.
-
On the art of identifying effective and specific siRNAs.Nat Methods. 2006 Sep;3(9):670-6. doi: 10.1038/nmeth911. Nat Methods. 2006. PMID: 16929310 Review.
-
Design and validation of siRNAs and shRNAs.Curr Opin Mol Ther. 2009 Apr;11(2):156-64. Curr Opin Mol Ther. 2009. PMID: 19330721 Review.
Cited by
-
Antiviral RNAi: translating science towards therapeutic success.Pharm Res. 2011 Dec;28(12):2966-82. doi: 10.1007/s11095-011-0549-8. Epub 2011 Aug 9. Pharm Res. 2011. PMID: 21826573 Free PMC article. Review.
-
Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization.Mol Ther Nucleic Acids. 2017 Sep 15;8:26-35. doi: 10.1016/j.omtn.2017.05.012. Epub 2017 Jun 1. Mol Ther Nucleic Acids. 2017. PMID: 28918027 Free PMC article.
-
Effects of Stuffer DNA on the Suppression of Choroidal Neovascularization by a rAAV Expressing a mTOR-Inhibiting shRNA.Mol Ther Methods Clin Dev. 2019 Jul 3;14:171-179. doi: 10.1016/j.omtm.2019.06.004. eCollection 2019 Sep 13. Mol Ther Methods Clin Dev. 2019. PMID: 31380463 Free PMC article.
-
Inhibition of mTOR via an AAV-Delivered shRNA Tested in a Rat OIR Model as a Potential Antiangiogenic Gene Therapy.Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):45. doi: 10.1167/iovs.61.2.45. Invest Ophthalmol Vis Sci. 2020. PMID: 32106292 Free PMC article.
-
Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis.Antimicrob Agents Chemother. 2012 Jul;56(7):3516-23. doi: 10.1128/AAC.06050-12. Epub 2012 Apr 16. Antimicrob Agents Chemother. 2012. PMID: 22508300 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources